GHRP 6, or growth hormone-releasing peptide-6, is a synthetic hexapeptide that acts as an agonist at the growth hormone secretagogue receptor, GHS-R1a, and is studied for its ability to stimulate growth hormone release from the pituitary. It was the first synthetic growth hormone secretagogue shown to have significant activity both in cultured pituitary cells and in whole animals, and it remains the reference compound against which later secretagogues in this class, including GHRP-2 and hexarelin, are compared. Laboratory research on GHRP 6 spans pituitary cell signalling, hypothalamic-pituitary interactions, and, more recently, cytoprotective effects reported outside the growth hormone axis. This article reviews the peptide’s structure, mechanism, the published preclinical literature, its research applications and the handling requirements relevant to a laboratory setting.
What is GHRP 6?
GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, consisting of six amino acid residues, including two D-configuration residues, with a C-terminal amide. It carries the developmental code name SK&F-110679 from its original discovery, and is sometimes referred to in the literature as growth hormone-releasing hexapeptide. Its free-base molecular weight is approximately 873 g/mol. As with other synthetic peptides of this size, research-grade material is commonly supplied as an acetate salt, which affects the mass reported on a certificate of analysis relative to the free-base peptide weight without altering the peptide’s own sequence or receptor activity.
GHRP-6 was discovered in the laboratory of Cyril Bowers, who had been investigating synthetic enkephalin-derived peptides since the late 1970s for their effects on growth hormone release from cultured rat pituitary cells. GHRP-6 was reported in 1984 as the first of these synthetic hexapeptides to show significant growth hormone-releasing activity in both cell culture and whole-animal models, specifically releasing growth hormone without concurrently affecting luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone or prolactin secretion. This selectivity, combined with its departure from the structure of growth hormone-releasing hormone itself, established GHRP-6 as the founding member of a distinct pharmacological class, later shown to act through a receptor separate from the growth hormone-releasing hormone receptor.
Mechanism of action
GHRP-6 acts on the growth hormone secretagogue receptor 1a (GHS-R1a), a seven-transmembrane G protein-coupled receptor expressed on pituitary somatotrophs and on neurons within the hypothalamic arcuate nucleus. This receptor was later identified, in 1999, as the endogenous target of ghrelin, which places GHRP-6 among a class of compounds now understood as ghrelin receptor agonists, discovered more than a decade before the receptor’s natural ligand was known.
Receptor engagement activates Gq/11-coupled phospholipase C, generating inositol trisphosphate and diacylglycerol. Inositol trisphosphate triggers release of calcium from intracellular stores, while diacylglycerol activates protein kinase C; the resulting rise in intracellular calcium is reported to drive exocytosis of growth hormone-containing secretory vesicles from somatotrophs. This pathway is mechanistically distinct from that of growth hormone-releasing hormone, which signals through a separate, Gs-coupled receptor and cyclic AMP, meaning GHRP-6 does not compete with growth hormone-releasing hormone for the same binding site despite producing an overlapping physiological outcome.
GHRP-6 is also reported to act at hypothalamic sites, in addition to its direct pituitary action, with central administration shown to produce greater growth hormone release relative to dose than peripheral administration, consistent with an additional site of action upstream of the pituitary. Somatostatin, the endogenous inhibitor of growth hormone release, has been shown to suppress GHRP-6-stimulated growth hormone release when administered centrally, which researchers have interpreted as evidence that GHRP-6 may act in part by stimulating growth hormone-releasing hormone-producing neurones that are themselves subject to somatostatin inhibition, rather than bypassing the hypothalamic axis entirely.
What the research shows
The foundational characterisation was reported by Bowers and colleagues in Endocrinology in 1984. The study combined rat pituitary cell culture experiments with in vivo administration in several species, reporting that the hexapeptide, referred to in the paper by its chemical designation, produced a dose-related release of growth hormone without concurrently releasing luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone or prolactin. The authors also reported that repeated subcutaneous administration to immature rats over periods of nine or twenty-five days increased body weight gain relative to controls, while the pituitary remained fully responsive to the peptide at the end of the study (Bowers et al., 1984, PubMed).
The receptor basis for this activity was examined in a binding study that characterised specific binding sites for the hexapeptide in hypothalamic and pituitary tissue. The investigators reported that binding affinity across a series of related peptides correlated significantly with their potency at releasing growth hormone, in both the hypothalamus and the pituitary, supporting the existence of a specific receptor mediating the peptide’s effects, ahead of the receptor’s formal molecular identification later in the 1990s (Codd et al., 1989, PubMed).
A study examining the relationship between GHRP-6 and the hypothalamic axis was published in the Journal of Endocrinology in 1995, using anaesthetised guinea pigs. The researchers reported that intracerebroventricular injection of GHRP-6 stimulated growth hormone release more than twentyfold more potently than intravenous injection at an equivalent dose, and that this centrally mediated growth hormone response could be inhibited by central somatostatin administration, consistent with an action at or upstream of growth hormone-releasing hormone-producing neurones in the hypothalamus (Conley et al., 1995, PubMed).
Human pharmacology has also been examined in the published literature, including a study assessing oral administration of the hexapeptide in healthy men and in children with short stature, which reported measurable increases in circulating growth hormone following oral dosing, alongside pharmacokinetic data on serum peptide levels. Because this and related human studies involved specific dosing protocols in named patient populations, readers wanting those details should consult the primary methods sections directly rather than a summary here. More recent review literature has also described a body of preclinical work on cytoprotective effects of GHRP-6 reported outside the growth hormone axis, including in cardiovascular tissue models, attributed to action at a second, as yet less well-characterised binding site distinct from GHS-R1a; this remains an active area of investigation rather than a settled mechanism.
Research applications
In the laboratory, GHRP 6 is used chiefly as a pharmacological tool for studying GHS-R1a signalling and pituitary growth hormone release. Pituitary cell culture models, both primary cells and immortalised lines, are treated with GHRP-6 to examine calcium, protein kinase C and growth hormone secretory pathway activity, often alongside growth hormone-releasing hormone for comparison, given the two compounds’ distinct receptor mechanisms and their reported synergy when administered together in some experimental systems.
Comparative pharmacology is a second major application. Because GHRP-6 was the first compound in its class and remains the best-characterised, researchers use it as a reference standard when evaluating newer growth hormone secretagogues and ghrelin receptor ligands, comparing relative potency, selectivity for growth hormone release over other pituitary hormones, and central versus peripheral routes of action, drawing on the central-versus-peripheral potency difference established in the guinea pig study described above.
Hypothalamic and whole-animal models are used to study the interaction between GHRP-6, growth hormone-releasing hormone and somatostatin within the broader neuroendocrine axis governing pulsatile growth hormone secretion. A more recent application, reflecting the cytoprotective literature noted above, uses GHRP-6 and related secretagogues in cell and animal models investigating effects outside the growth hormone axis, including studies of tissue protection under conditions of injury or stress, an area of ongoing preclinical research rather than an established application.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing GHRP 6 should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the target hexapeptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Mass spectrometry alongside HPLC confirms identity against the expected free-base mass of approximately 873 daltons, with the observed mass differing where the material is supplied as an acetate salt; a batch-specific certificate of analysis should report both the peptide purity and the salt content separately. This batch-specific documentation, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected experimental data to be traced back to a defined lot.
Lyophilised GHRP-6 should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk degrading the peptide. The two tryptophan residues within the sequence are particularly susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions during handling. Published reconstituted-stability data specific to GHRP-6 are limited in the open literature, so laboratories should validate their own working window empirically, for example by re-running HPLC on aliquots at defined time points.
Frequently asked questions
What is GHRP 6 used for in research?
It is used mainly as a pharmacological tool for studying growth hormone secretagogue receptor (GHS-R1a) signalling, pituitary calcium and protein kinase C pathways, and the hypothalamic-pituitary axis governing growth hormone release, alongside comparative pharmacology against related compounds such as GHRP-2 and hexarelin. It is not approved as a medicine, and nothing here concerns use in humans.
What is the difference between GHRP-6 and GHRP-2?
Both are synthetic hexapeptide agonists of the GHS-R1a receptor, with GHRP-6 being the earlier, founding compound in the class and GHRP-2 a later analogue developed with the aim of improving potency and selectivity. Published comparisons generally describe GHRP-2 as producing less accompanying cortisol and prolactin release than GHRP-6 at growth hormone-releasing doses, though both act through the same receptor mechanism.
How should GHRP 6 be stored once reconstituted?
Reconstituted GHRP-6 should be divided into single-use aliquots, kept refrigerated only briefly and otherwise frozen, protected from light, and not subjected to repeated freeze–thaw cycles. Because specific published stability data are limited, laboratories should confirm their own storage window empirically, for example with HPLC comparisons of fresh and aged aliquots.
Does GHRP-6 act through the same receptor as GHRH?
No. GHRP-6 acts on the growth hormone secretagogue receptor (GHS-R1a), a Gq/11-coupled receptor later shown to be the endogenous ghrelin receptor, whereas growth hormone-releasing hormone acts on a separate, Gs-coupled receptor linked to cyclic AMP. Because the two pathways are mechanistically distinct, researchers have reported their combined effects on growth hormone release exceed either compound given alone in some experimental systems.
The GHRP 6 discussed in this article is supplied for in-vitro and in-vivo laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
